KR102618947B1 - 뇌 질환을 치료하기 위한 방법 및 조성물 - Google Patents

뇌 질환을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102618947B1
KR102618947B1 KR1020177020915A KR20177020915A KR102618947B1 KR 102618947 B1 KR102618947 B1 KR 102618947B1 KR 1020177020915 A KR1020177020915 A KR 1020177020915A KR 20177020915 A KR20177020915 A KR 20177020915A KR 102618947 B1 KR102618947 B1 KR 102618947B1
Authority
KR
South Korea
Prior art keywords
aav
mice
rhes
subject
mtorc1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177020915A
Other languages
English (en)
Korean (ko)
Other versions
KR20170098931A (ko
Inventor
비벌리 엘. 데이비슨
존 에이치. 리
Original Assignee
유니버시티 오브 아이오와 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 아이오와 리써치 파운데이션 filed Critical 유니버시티 오브 아이오와 리써치 파운데이션
Publication of KR20170098931A publication Critical patent/KR20170098931A/ko
Application granted granted Critical
Publication of KR102618947B1 publication Critical patent/KR102618947B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177020915A 2014-12-30 2015-12-30 뇌 질환을 치료하기 위한 방법 및 조성물 Active KR102618947B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
US62/098,085 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (2)

Publication Number Publication Date
KR20170098931A KR20170098931A (ko) 2017-08-30
KR102618947B1 true KR102618947B1 (ko) 2023-12-27

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020915A Active KR102618947B1 (ko) 2014-12-30 2015-12-30 뇌 질환을 치료하기 위한 방법 및 조성물

Country Status (12)

Country Link
US (1) US11612641B2 (cg-RX-API-DMAC7.html)
EP (1) EP3240577B1 (cg-RX-API-DMAC7.html)
JP (1) JP6782701B2 (cg-RX-API-DMAC7.html)
KR (1) KR102618947B1 (cg-RX-API-DMAC7.html)
CN (1) CN107405414A (cg-RX-API-DMAC7.html)
AU (1) AU2015374043B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017013674A2 (cg-RX-API-DMAC7.html)
CA (1) CA2971687C (cg-RX-API-DMAC7.html)
ES (1) ES2962439T3 (cg-RX-API-DMAC7.html)
SG (1) SG11201704829QA (cg-RX-API-DMAC7.html)
WO (1) WO2016109649A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201704327B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018132791A1 (en) * 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
JP2008539276A (ja) 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
KR101286870B1 (ko) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 황기 추출물을 포함하는 대사 촉진 조성물
SG11201401716XA (en) * 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
WO2013067125A1 (en) * 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
CN104080786A (zh) 2011-11-08 2014-10-01 因特利凯有限责任公司 使用多种药剂的治疗方案
US9095521B2 (en) * 2012-02-02 2015-08-04 Washington University Methods for improving muscle strength
KR101626526B1 (ko) 2014-10-30 2016-06-02 경북대학교 산학협력단 hRheb를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
WO2016109649A1 (en) 2014-12-30 2016-07-07 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2013. 43rd Annual Meeting of the Society-For-Neuroscience.(Poster #306.05)(2013.11.11.)*
Journal of Biological Chemistry. 2006. Vol.281, No.29, pp.19793-19797.*
Molecular Therapy. 2012. Vol.20, No.2, pp.275-286.*

Also Published As

Publication number Publication date
CA2971687C (en) 2024-05-28
JP2018502112A (ja) 2018-01-25
CA2971687A1 (en) 2016-07-07
AU2015374043B2 (en) 2021-05-13
JP6782701B2 (ja) 2020-11-11
EP3240577B1 (en) 2023-07-05
AU2015374043A1 (en) 2017-07-13
ES2962439T3 (es) 2024-03-19
ZA201704327B (en) 2025-02-26
KR20170098931A (ko) 2017-08-30
US20180000907A1 (en) 2018-01-04
HK1245127A1 (en) 2018-08-24
BR112017013674A2 (pt) 2018-02-06
US11612641B2 (en) 2023-03-28
NZ733014A (en) 2024-05-31
EP3240577A1 (en) 2017-11-08
SG11201704829QA (en) 2017-07-28
CN107405414A (zh) 2017-11-28
EP3240577A4 (en) 2018-07-25
WO2016109649A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
US20240226203A9 (en) Compositions and methods of treating huntington's disease
US20230295663A1 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
AU2018352236B2 (en) Treatment of amyotrophic lateral sclerosis (ALS)
EP3240577B1 (en) Therapeutic agent that activates mtorc1 function for use in treating huntington's disease
US20200270635A1 (en) Modulatory polynucleotides
US11155817B2 (en) Therapeutic for treatment of diseases including the central nervous system
JP2006521825A (ja) rAAV導入を高めるための化合物および方法
EP2187898B1 (en) Use of viral vectors carrying the cyp46a1 gene for the treatment of alzheimer's disease
US20240343768A1 (en) Gene therapy for tuberous sclerosis
CN112955169A (zh) 用于肌萎缩性侧索硬化疗法中的胆固醇24-水解酶的表达载体
US10512698B2 (en) Method for genetic treatment using the AAV-XBP1s/GFP virus and use thereof in the prevention and treatment of amyotrophic lateral sclerosis
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
WO2020223475A1 (en) Methods and compositions involving tert activating therapies
KR20240150772A (ko) 폴리q 질환 치료를 위한 치료 인자
HK1245127B (en) Therapeutic agent that activates mtorc1 function for use in treating huntington's disease
WO2025015328A2 (en) Increasing nfe2l1 activity or expression as therapy for eye disorders
JP2022531177A (ja) 神経変性障害を治療するための方法
HK40052708B (en) Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
HK40052708A (zh) 用於肌萎缩性侧索硬化疗法中的胆固醇24-羟化酶的表达载体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170726

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230313

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230925

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231222

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231222

End annual number: 3

Start annual number: 1

PG1601 Publication of registration